Welcome to our dedicated page for Herbal Dispatch news (Ticker: LUFFF), a resource for investors and traders seeking the latest updates and insights on Herbal Dispatch stock.
Herbal Dispatch Inc. reports developments in cannabis e-commerce and distribution, including medical cannabis platforms, direct-to-consumer ordering, and product-channel expansion. Company updates have covered HerbalDispatch.com, the HeroDispatch platform for veterans and insured medical patients, concierge-style support, clinic integration, and insurance-backed purchasing.
Recurring news themes include growth in veteran customer acquisition, enhancements to Shopify-based e-commerce infrastructure, the Chomp Edibles brand, operating and financial results, capital-structure updates such as DTC eligibility, and governance changes tied to board leadership and strategic oversight.
Herbal Dispatch (OTCQB: LUFFF) completed its first international export of medical cannabis gummies to Australia on April 30, 2026, generating approximately $350,000 in revenue.
The shipment was sold to a top-three global cannabis company and marks a step in the company's global edibles strategy, with additional follow-on shipments anticipated in 2026 subject to regulatory approvals.
Herbal Dispatch (OTCQB: LUFFF) launched its first edible brand, Chomp Edibles, expanding into Canada’s growing edibles market with craft-inspired gummies in Grape, Cherry Coke, Cherry, Freshly Squeezed Orange and Blueberry.
Chomp offers multiple dosing and pack formats (5mg, 10mg single, 10x and 20x master packs), aligns with recent regulatory changes, and is available via the company’s medical, veteran and select wholesale channels nationwide. Q1 2025 edibles made ~26% of packaged units; the Canadian market reached about $5.2B in annual sales.
Herbal Dispatch (OTCQB: LUFFF) announced it is advancing a U.S. strategy after the U.S. Department of Health and Human Services recommended reclassifying cannabis from Schedule I to Schedule III on April 27, 2026. The company is evaluating partnerships, joint ventures and platform-led, asset-light entry into regulated U.S. medical channels while maintaining Canadian operations.
Herbal Dispatch highlights its patient-acquisition, insurance-supported programs and DTC eligibility as positioning advantages and says rescheduling could improve profitability, access to capital and sector re-rating.
Herbal Dispatch (OTCQB: LUFFF) reported Q4 2025 gross sales of $6.2M (up 115% YoY) and FY2025 gross sales of $16.5M (up 37% YoY). Net revenue was $4.1M in Q4 and $12.1M for FY2025. Adjusted EBITDA was positive $0.1M in Q4 and negative $0.7M for FY2025, with gross margin improving to ~22.7%.
The company raised $2.1M in an oversubscribed private placement in October 2025 and began trading on the OTCQB under LUFFF after year end.
Herbal Dispatch (OTCQB: LUFFF) appointed the Honourable Herb Dhaliwal as a full-time Board member and Chairman effective April 23, 2026. Mr. Dhaliwal is a former Member of Parliament and served as Minister of National Revenue, Natural Resources, and Fisheries and Oceans. The company said his regulatory and public‑policy experience will support Canadian and international expansion and strengthen governance.
Herbal Dispatch (OTCQB: LUFFF) announced its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC), improving accessibility for U.S. investors and expected to enhance liquidity and visibility in North America. The company also engaged a market maker and extended certain marketing partner agreements to June 30, 2026.
The company confirmed allocated marketing capital remains available and deferred campaign execution pending DTC eligibility; market making services will be provided for a monthly fee of $5,000.
Herbal Dispatch (OTCQB: LUFFF) amended its unsecured convertible debentures, extending the maturity date from January 31, 2026 to January 31, 2028. All other terms remain: 14% annual interest, conversion price CAD$0.06, and threshold price CAD$0.12.
The company obtained a CSE exemption for certain amendment requirements and relied on MI 61-101 exemptions for formal valuation and minority approval as the fair market values were under 25% of market capitalization. Both director-noteholders abstained from the Board vote; no material change report was filed 21 days prior due to ongoing negotiations.
Herbal Dispatch (OTCQB: LUFFF) announced that its common shares commenced trading on the OTCQB Venture Market effective January 26, 2026 under the ticker LUFFF. The listing is intended to enhance accessibility for U.S. investors, broaden North American exposure, and complement the company’s primary CSE listing (HERB) and Frankfurt listing (HA9). Management said the OTCQB listing may improve liquidity and visibility for U.S. shareholders and supports the company’s capital markets strategy amid renewed investor interest tied to U.S. federal policy momentum on cannabis rescheduling. Investors are directed to the company investor page for reports and updates.
Herbal Dispatch (OTC: LUFFF) reported operational milestones for 2025, including a third consecutive year of double-digit annual sales growth. Preliminary Q4 2025 gross sales were $6.2M (214% vs Q4 2024), and preliminary fiscal 2025 gross sales were $16.5M (38% vs $12.0M in 2024). The company completed an oversubscribed $2.0M private placement in October and launched multiple in-house brands (flower, pre-rolls, vape). The company said Q4 gross margins are expected to be similar to recent quarters and outlined 2026 strategic priorities targeting veteran medical sales, 40% YoY recreational growth, expanded BC SKUs, and tripling exports by 2028.
Herbal Dispatch (OTC Pink: LUFFF) CEO Philip Campbell commented on the U.S. rescheduling of cannabis from Schedule I to Schedule III, calling it a transformative development with global implications for medical research and cross‑border market harmonization.
The company said the change could create strategic partnership and market access opportunities between U.S. and Canadian markets and said it may improve capital access for technology and supply‑chain investments. The release also discloses paid promotional engagements and compensation details to comply with CSE policy.